Relationship between serum adipocyte fatty acid-binding protein and endothelial/hemostatic markers in dyslipidemic subjects

Neuroendocrinology Letters

Volumn 33, Issue SUPPL. 2, 2012, Pages 26-31

  Karasek, David ^a   Vaverkova, Helena ^a   Frysak, Zdenek ^a   Orsag, Jiri ^a   Novotny, Dalibor ^a   Halenka, Milan ^a   Slavik, Ludek ^a  

^a UNIVERSITY HOSPITAL OLOMOUC   (Czech Republic)

Author keywords

Adhesion molecules; Adipocyte fatty acid binding protein; Dyslipidemia; Plasminogen activator inhibitor 1; Tissue plasminogen activator; Von Willebrand factor

Indexed keywords

APOLIPOPROTEIN B; C REACTIVE PROTEIN; FATTY ACID BINDING PROTEIN 4; INSULIN; INTERCELLULAR ADHESION MOLECULE 1; PLASMINOGEN ACTIVATOR INHIBITOR 1; TISSUE PLASMINOGEN ACTIVATOR; TRIACYLGLYCEROL; VASCULAR CELL ADHESION MOLECULE 1; VON WILLEBRAND FACTOR;

ADULT; AGE; BODY MASS; CASE CONTROL STUDY; CONFERENCE PAPER; CONTROLLED STUDY; DYSLIPIDEMIA; ENDOTHELIAL DYSFUNCTION; FEMALE; GENDER; HEMOSTASIS; HOMEOSTATIC MODEL ASSESSMENT INDEX; HUMAN; INFLAMMATION; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; OBESITY; PROTEIN BLOOD LEVEL; SCORING SYSTEM; TRIACYLGLYCEROL BLOOD LEVEL; WAIST CIRCUMFERENCE;

EID: 84871102554     PISSN: 0172780X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (34)

1. Agardh HE, Folkersen L, Ekstrand J, Marcus D, Swedenborg J, Hedin U, et al (2011). Expression of fatty acid-binding protein 4/ aP2 is correlated with plaque instability in carotid atherosclerosis. J Intern Med. 269: 200-210.
2. Bao Y, Lu Z, Zhou M, Li H, Wang Y, Gao M, et al (2011). Serum levels of adipocyte fatty acid-binding protein are associated with the severity of coronary artery disease in Chinese women. PLoS One. 6: e19115.
3. Blankenberg S, Barbaux S, Tiret L (2003). Adhesion molecules and atherosclerosis. Atherosclerosis. 170: 191-203. (Pubitemid 37377790)
4. Campos H, Blijlevens E, McNamara JR, Ordovas JM, Posner BM, Wilson PW, et al (1992). LDL particle size distribution. Results from the Framingham Offspring Study. Arterioscler Thromb. 12: 1410-1419.
5. Demacker PN, Veerkamp MJ, Bredie SJ, Marcovina SM, de Graaf J, Stalenhoef AF (2000). Comparison of the measurement of lipids and lipoproteins versus assay of apolipoprotein B for estimation of coronary heart disease risk: a study in familial combined hyperlipidemia. Atherosclerosis. 153: 483-490. (Pubitemid 32120348)
6. Doi M, Miyoshi T, Hirohata S, Nakamura K, Usui S, Takeda K, et al (2011). Association of increased plasma adipocyte fatty acid-binding protein with coronary artery disease in non-elderly men. Cardiovasc Diabetol. 10: 44.
7. Galkina E, Ley K (2007). Vascular adhesion molecules in atherosclerosis. Arterioscler Thromb Vasc Biol. 27: 2292-2301. (Pubitemid 350203942)
8. Garanty-Bogacka B, Syrenicz M, Syrenicz A, Gebala A, Walczak M (2005). Relation of acute-phase reaction and endothelial activation to insulin resistance and adiposity in obese children and adolescents. Neuro Endocrinol Lett. 26: 473-479. (Pubitemid 43013717)
9. Hoo RC, Yeung CY, Lam KS, Xu A (2008). Inflammatory biomarkers associated with obesity and insulin resistance: a focus on lipocalin-2 and adipocyte fatty acid-binding protein. Expert Rev Endocrinol Metab. 3: 29-41.
10. Horakova D, Pastucha D, Stejskal D, Kollarova H, Azeem K, Janout V (2011). Adipocyte Fatty Acid binding protein and C-reactive protein levels as indicators of insulin resistance development. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 155: 355-359.
11. Hsu BG, Chen YC, Lee RP, Lee CC, Lee CJ, Wang JH (2010). Fasting serum level of fatty-acid-binding protein 4 positively correlates with metabolic syndrome in patients with coronary artery disease. Circ J. 74: 327-331.
12. Hui X, Li H, Zhou Z, Lam KS, Xiao Y, Wu D, et al (2010). Adipocyte fatty acid-binding protein modulates inflammatory responses in macrophages through a positive feedback loop involving c-Jun NH2-terminal kinases and activator protein-1. J Biol Chem. 285: 10273-10280.
13. Karasek D, Vaverkova H, Halenka M, Jackuliakova D, Frysak Z, Slavik L, et al (2011 a). Prothrombotic markers in asymptomatic dyslipidemic subjects. J Thromb Thrombolysis. 31: 27-36.
14. Karasek D, Vaverkova H, Frysak Z, Halenka M, Jackuliakova D, Novotny D, et al (2011b). Soluble intercellular cell adhesion molecule-1 and vascular cell dhesion molecule-1 in asymptomatic dyslipidemic subjects. Int Angiol. 30: 441-450.
15. Kawakami A, Aikawa M, Alcaide P, Luscinskas FW, Libby P, Sacks FM (2006). Apolipoprotein CIII induces expression of vascular cell adhesion molecule-1 invascular endothelial cells and increases adhesion of monocytic cells. Circulation. 114: 681-687. (Pubitemid 44252310)
16. Kohler HP, Grant PJ (2000). Plasminogen-activator inhibitor type 1 and coronary artery disease. N Engl J Med. 342: 1792-1801. (Pubitemid 30390240)
17. Lee KW, Lip GY, Tayebjee M, Foster W, Blann AD (2005). Circulating endothelial cells, von Willebrand factor, interleukin-6, and prognosis in patients with acute coronary syndromes. Blood. 105: 526-532. (Pubitemid 40070731)
18. Lee MY, Li H, Xiao Y, Zhou Z, Xu A, Vanhoutte PM (2011). Chronic administration of BMS309403 improves endothelial function in apolipoprotein E-deficient mice and in cultured human endothelial cells. Br J Pharmacol. 162: 1564-1576.
19. Liang YJ, Ma XC, Li X (2010). The role of p38 mitogen-activated protein kinase/nuclear factor-KB transduction pathway on coagulation disorders due to endothelial injury induced by sepsis. Zhongguo Wei Zhong Bing Ji Jiu Yi Xue. 22: 528-532.
20. Makin AJ, Blan AD, Chung NA, Silverman SH, Lip GY (2004). Assessment of endothelial damage in atherosclerotic vascular disease by quantification of circulating endothelial cells. Relationship with von Willebrand factor and tissue factor. Eur Heart J. 25: 371-376. (Pubitemid 38391518)
21. Makowski L, Brittingham KC, Reynolds JM, Suttles J, Hotamisligil GS (2005). The fatty acid-binding protein, aP2, coordinates macrophage cholesterol trafficking and inflammatory activity. Macrophage expression of aP2 impacts peroxisome proliferator-activated receptor gamma and IkappaB kinase activities. J Biol Chem. 280: 12888-12895.
22. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC (1985). Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 28: 412-419. (Pubitemid 15018832)
23. Miyoshi T, Onoue G, Hirohata A, Hirohata S, Usui S, Hina K, et al (2010). Serum adipocyte fatty acid-binding protein is independently associated with coronary atherosclerotic burden measured by intravascular ultrasound. Atherosclerosis. 211: 164-169.
24. Park SE, Rhee EJ, Lee WY, Kim WJ, Yoo SH, Bae JC, et al (2012). The role of serum adipocyte fatty acid-binding protein on the development of metabolic syndrome is independent of pro-inflammatory cytokines. Nutr Metab Cardiovasc Dis. 22: 525-532.
25. Pierce GL, Lesniewski LA, Lawson BR, Beske SD, Seals DR (2009). Nuclear factor-{kappa}B activation contributes to vascular endothelial dysfunction via oxidative stress in overweight/obese middle-aged and older humans. Circulation. 119: 1284-1292.
26. Rhee EJ, Lee WY, Park CY, Oh KW, Kim BJ, Sung KC, et al (2009). The association of serum adipocyte fatty acid-binding protein with coronary artery disease in Korean adults. Eur J Endocrinol. 160: 165-172.
27. Smith A, Patterson C, Yarnell J, Rumley A, Ben-Shlomo Y, Lowe G (2005). Which hemostatic markers add to the predictive value of conventional risk factors for coronary heart disease and ischemic stroke? The Caerphilly Study. Circulation. 112: 3080-3087. (Pubitemid 43113439)
28. Tso AW, Lam TK, Xu A, Yiu KH, Tse HF, Li LS, et al (2011). Serum adipocyte fatty acid-binding protein associated with ischemic stroke and early death. Neurology. 76: 1968-1975.
29. Tso AW, Xu A, Sham PC, Wat NM, Wang Y, Fong CH, et al (2007). Serum adipocyte fatty acid binding protein as a new biomarker predicting the development of type 2 diabetes: a 10-year prospective study in a Chinese cohort. Diabetes Care. 30: 2667-2672. (Pubitemid 47547818)
30. Xiao Y, Yao L, Li X, Zhong H, Chen XY, Tang WL, et al (2010). Relationship of adipocyte fatty acid-binding protein to adiponectin ratio with femoral intima-media thickness and endothelium-dependent vasodilation in patients with newly-diagnosed type 2 diabetes mellitus. Zhonghua Yi Xue Za Zhi. 90: 231-235.
31. Xu A, Tso AW, Cheung BM, Wang Y, Wat NM, Fong CH, et al (2007) Circulating adipocyte-fatty acid binding protein levels predict the development of the metabolic syndrome: a 5-year prospective study. Circulation. 115: 1537-1543. (Pubitemid 46648638)
32. Xu A, Vanhoutte PM (2012). Adiponectin and adipocyte fatty acid binding protein in the pathogenesis of cardiovascular disease. Am J Physiol Heart Circ Physiol. 302: H1231-H1240.
33. Xu A, Wang Y, Xu JY, Stejskal D, Tam S, Zhang J, et al (2006). Adipocyte fatty acid-binding protein is a plasma biomarker closely associated with obesity and metabolic syndrome. Clin Chem. 52: 405-413.
34. Yeung DC, Xu A, Cheung CW, Wat NM, Yau MH, Fong CH, et al (2007). Serum adipocyte fatty acid-binding protein levels were independently associated with carotid atherosclerosis. Arterioscler Thromb Vasc Biol. 27: 1796-1802. (Pubitemid 47207176)